ACS
PACB icon

Archford Capital Strategies’s Pacific Biosciences PACB Stock Holding History

Archford Capital Strategies’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,194
Closed -$65.5K – 348
2025
Q3 		$65.5K Sell
51,194
-1,500
-3% -$2.03K 0.01% 323
2025
Q2 		$65.3K Hold
52,694
– – 0.01% 320
2025
Q1 		$62.2K Hold
52,694
– – 0.01% 289
2024
Q4 		$96.4K Sell
52,694
-1
-0% -$2 0.01% 265
2024
Q3 		$108K Hold
52,695
– – 0.02% 252
2024
Q2 		$72.2K Sell
52,695
-18,063
-26% -$36.5K 0.01% 256
2024
Q1 		$265K Buy
70,758
+50,734
+253% +$297K 0.04% 232
2023
Q4 		$196K Sell
20,024
-53,660
-73% -$439K 0.04% 246
2023
Q3 		$615K Sell
73,684
-162
-0.2% -$1.85K 0.12% 168
2023
Q2 		$952K Sell
73,846
-393
-0.5% -$4.78K 0.18% 133
2023
Q1 		$814K Buy
74,239
+760
+1% +$7.56K 0.17% 138
2022
Q4 		$601K Sell
73,479
-9,183
-11% -$79.1K 0.14% 171
2022
Q3 		$480K Buy
82,662
+8,089
+11% +$46.4K 0.12% 184
2022
Q2 		$330K Buy
74,573
+1,278
+2% +$7.77K 0.08% 217
2022
Q1 		$693K Buy
73,295
+1,458
+2% +$16.8K 0.15% 150
2021
Q4 		$1.47M Sell
71,837
-1,209
-2% -$29.2K 0.34% 77
2021
Q3 		$1.87M Buy
73,046
+326
+0.4% +$9.66K 0.44% 53
2021
Q2 		$2.54M Buy
72,720
+2,588
+4% +$75.3K 0.64% 33
2021
Q1 		$2.3M Buy
70,132
+6,032
+9% +$211K 0.61% 36
2020
Q4 		$2.35M Buy
64,100
+7,000
+12% +$119K 0.54% 50
2020
Q3 		$564K Buy
+57,100
New +$329K 0.15% 162

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Archford Capital Strategies's PACB Position: Q4 2025 in Review

Archford Capital Strategies sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 51,194 shares — an estimated $65.5K sold.

Archford Capital Strategies first reported a position in PACB in Q3 2020 and held it in 21 quarters. The position peaked at $2.54M in Q2 2021. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

  • Archford Capital Strategies reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
  • Archford Capital Strategies sold 51,194 Pacific Biosciences shares in Q4 2025, an estimated $65.5K.
  • Archford Capital Strategies first reported a position in Pacific Biosciences in Q3 2020 and held it in 21 quarters.
  • Archford Capital Strategies's Pacific Biosciences position peaked at $2.54M in Q2 2021.
  • 215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Archford Capital Strategies's 13F filing for Q4 2025, filed 15 Jan 2026.